CNH’s Post

More Relevant Posts

  • View profile for Dominique Raviart, graphic
    Dominique Raviart

    Practice Director at NelsonHall around IT services. Blogs about engineering and ER&D services #ITservices #ERDservices

    CGI's Q1 FY24 earnings (ending December 31, 2023) were out last week and went noticed (all percentages are y/y in CC): ● Revenue growth was +1.5% thanks to the US Federal (+3.8%), and UK & Australia (+6.2%) ● EBIT margin was 14.6%, down 40 bps (restructuring impact) ● Net debt was down 26% to CAD 1.8bn. A few thoughts: ● CGI beats many tier-one #ITservices vendors: Infosys (-1.0%), Wipro,(-6.9%), and Tech Mahindra (-5.4%) and is in line with Tata Consultancy Services (+1.7%) ● CGI benefits from its exposure to government (36% of revenues, up 7.5%) and IP (+4.2%). Softness in banking continues. The company continues to target managed services deals, especially when combined with IP. Managed services bookings were up, despite a slow conversion into revenues ● CGI beat most competitors thanks to its vertical mix, which is heavy on government, and lighter on telecom and high-tech - Infosys was hit in BFSI (-5.9%), Communication (-8.0%), and high-tech (-5.1%) - Wipro suffered from its exposure to BFSI (-13.2%) and Communications (-19.2%) - Tech Mahindra was impacted in CME (-13.4%), its largest vertical, and BFSI (-7.8%) In other words, this year, like last year, the performance of IT services vendors is governed by their geographic and vertical mix. HCLTech managed to do very well in TME thanks to its Verizon mega-deal.

    To view or add a comment, sign in

  • View profile for Sabrina Johnson, graphic
    Sabrina Johnson

    President and CEO, DARÉ Bioscience (NASDAQ:DARE)

    Yesterday, Daré Bioscience, Inc. announced full year 2023 financial results, showing once again that we’ve built the premier company in women’s health with the broadest portfolio of potentially first-in-category product candidates. We made significant strides in 2023 to advance innovative therapies for women and position ourselves well for the milestones to come in 2024. In 2023 alone, we announced the first shipment of XACIATO™ in connection with its launch in the United States, had 15 interactions with the FDA across six product candidates / indications, commenced the pivotal Phase 3 study for our hormone-free monthly intravaginal contraceptive candidate Ovaprene, successfully completed the Phase 2b study of our investigational Sildenafil Cream product in female sexual arousal disorder and the DARE-PDM1 vaginal diclofenac for menstrual pain Phase 1 study, and received IND clearance for DARE-VVA1, our hormone-free treatment for sexual pain. I’m also excited about the increased attention that women’s health has received more broadly since the White House announced the first-ever initiative on women’s health research in November, an effort led by First Lady Dr. Jill Biden and the White House Gender Policy Council, which emphasized that to “achieve scientific breakthroughs and strengthen our ability to prevent, detect, and treat diseases, we have to be bold.” (Oh yes, we do, and we are – and personally, it’s rewarding to see that language given in English, “Daré” means “to be bold”!) I’ve also had the pleasure of attending in person both the ARPA-H announcement with Dr. Biden in Boston last month and the signing of the executive order at the White House just last week – all moments that remind me just how much we can accomplish by bringing focus and investment to the entire ecosystem to boldly innovate for women. Our achievements, coupled with these recent industry developments, underscore what a fantastic time it is to be working in women’s health, and the significant opportunity in this space. But most importantly, our achievements in 2023 demonstrate that our approach to accelerating clinical development works, and that our leading programs have disruptive potential in the conditions and populations they aim to treat. None of these successes would have been possible without the Daré team’s unwavering commitment to advancing innovation for women’s health, which continues to drive our progress. I look forward to building on this momentum as we continue to accelerate therapies that increase options, improve outcomes, and offer convenience for women’s most persistent unmet needs. Learn more about our financial results and company update here: https://bit.ly/3VwTx33

    View organization page for Daré Bioscience, Inc., graphic
    Daré Bioscience, Inc.

    4,010 followers

    Today, we announced our full year 2023 financial results. To hear our company update, join this afternoon’s call by dialing in or by visiting “Presentations, Events & Webcasts" in the Investors section of our website: https://lnkd.in/eRzQdk5U

    • No alternative text description for this image

    To view or add a comment, sign in

CNH

752,498 followers

View Profile

Explore topics